Background Conflicting findings exist on the benefit of withdrawal of inhaled corticosteroid
(ICS) in chronic obstructive pulmonary disease (COPD). We performed a quantitative …

Current guidelines for the management of chronic obstructive pulmonary disease (COPD)
recommend limiting the use of inhaled corticosteroids (ICS) to patients with more severe …

International guidance on chronic obstructive pulmonary disease (COPD) management
recommends the use of inhaled corticosteroids (ICS) in those patients at increased …

Inhaled corticosteroids (ICS) reduce COPD exacerbation frequency and slow decline in
health related quality of life but have little effect on lung function, do not reduce mortality, and …

Background It has been suggested that withdrawal of inhaled corticosteroids (ICS) in COPD
patients on maintenance treatment results in deterioration of symptoms, lung function and …

Background The use of inhaled corticosteroids (ICS) in combination with bronchodilators in
patients with COPD has been shown to decrease the rate of disease exacerbations and to …

Inhaled corticosteroids (ICS) combined with bronchodilators can reduce the frequency of
exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There …

Background Guidelines recommend inhaled corticosteroids (ICS) for patients with severe
chronic obstructive pulmonary disease (COPD). Most COPD patients are managed in …

The use of inhaled corticosteroids (ICS) in the treatment of chronic obstructive pulmonary
disease (COPD) has been widely debated [1–3]. Treatment guidelines have suggested that …

According to the current clinical practice guidelines for chronic obstructive pulmonary
disease (COPD), the addition of inhaled corticosteroids (ICS) to long-acting β 2 agonist …